a
Departamento de Farmacología, Centro de Investigación y de
Estudios Avanzados del IPN, Apartado postal 14-740, Zacatenco 07000,
México D.F, Mexico
b
Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina del IPN, México D.F, Mexico
c
Unidad de Biomedicina (UBIMED), FES-Iztacala, Universidad Nacional Autónoma de México (UNAM), Estado de México, Mexico
d
Departamento de Farmacología, Centro de Investigación y de
Estudios Avanzados del IPN, Avenida Instituto Politécnico Nacional 2508,
México D.F, 07360, Mexico
We investigated the effect of inter-renal aortic coarctation on the function and expression of vascular a1A- and a1D-adrenoceptors and plasma angiotensin II (ATII) in rats. Male Wistar rats, either sham operated (SO), or with aortic coarctation for 7 (AC7) and 14 days (AC14) were used for agonist-induced pressor responses in vehicle (physiological saline)- and antagonist-treated anesthetized animals, immunoblot analysis (α1A- and α1D-adrenoceptor in aorta and caudal arteries), and immunoassay (plasma ATII). The a1D-adrenoceptor antagonist, BMY-7378 (BMY) blocked noradrenalineinduced responses in the order SO > AC7 ≫ AC14; in contrast, the α1A-adrenoceptor antagonist RS-100329 (RS), produced a marginal shift to the right of the dose-response curve to noradrenaline, along with a strong decrease of the maximum pressor effect in the order SO > AC7 = AC14. The potency of the α1A-adrenoceptor agonist A-61603 increased in rats with AC14, and responses were inhibited by RS in the order AC14 > AC7 > SO. In aorta, α1D-adrenoceptor protein increased in AC7 and decreased in AC14; α1A-adrenoreceptor protein increased in the caudal artery of AC7 and returned to control values in AC14. Plasma ATII increased in AC7 and AC14, compared with SO rats. These results suggest an early and direct relationship between ATII and a1D-adrenoreceptors in the development of hypertension in this experimental model.
Angiotensin ii; Aortic coarctation-induced hypertension; Rats; Vascular α1D-adrenoceptors
EMTREE drug terms: (5 methyl 3 [3 [3 [4 [2 (2,2,2, trifluroethoxy)phenyl] 1 piperazinyl]propyl] 2,4 (1h,3h) pyrimidinedione hydrochloride; 5 methyl 3 [3 [4 [2 (2,2,2 trifluoroethoxy)phenyl] 1 piperazinyl]propyl] 1h pyrimidine 2,4 dione; 8 [2 [4 (2 methoxyphenyl) 1 piperazinyl]ethyl] 8 azaspiro[4.5]decane 7,9 dione; alpha 1 adrenergic receptor blocking agent; alpha 1A adrenergic receptor; alpha 1D adrenergic receptor; angiotensin II; n [5 (4,5 dihydro 1h imidazol 2 yl) 5,6,7,8 tetrahydro 2 hydroxy 1 naphthyl]methanesulfonamide; noradrenalin; unclassified drug
EMTREE medical terms: angiotensin blood level; animal experiment; animal model; aorta coarctation; article; controlled study; dose response; hypertension; male; nonhuman; priority journal; protein expression; protein function; rat; sham procedure
MeSH: Adrenergic alpha-1 Receptor Agonists; Adrenergic
alpha-1 Receptor Antagonists; Angiotensin II; Animals; Aorta; Aortic
Coarctation; Dose-Response Relationship, Drug; Hypertension,
Renovascular; Imidazoles; Male; Norepinephrine; Piperazines; Rats; Rats,
Wistar; Receptors, Adrenergic, alpha-1; Tetrahydronaphthalenes; Thymine
Medline is the source for the MeSH terms of this document.
Chemicals and CAS Registry Numbers: 8 [2 [4 (2 methoxyphenyl) 1 piperazinyl]ethyl] 8 azaspiro[4.5]decane 7,9 dione, 21102-94-3; angiotensin II, 11128-99-7; n [5 (4,5 dihydro 1h imidazol 2 yl) 5,6,7,8 tetrahydro 2 hydroxy 1 naphthyl]methanesulfonamide, 107756-30-9, 167883-21-8, 168570-25-0; noradrenalin, 1407-84-7, 51-41-2;A 61603; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Angiotensin II, 11128-99-7; BMY 7378, 21102-94-3; Imidazoles; Norepinephrine, 51-41-2; Piperazines; RS 100329; Receptors, Adrenergic, alpha-1; Tetrahydronaphthalenes; Thymine, 65-71-4
Drug tradename: a 61603,bmy 7378,rs 100329.
Terrón, J. A.; Departamento de Farmacología, Centro de Investigación y
de Estudios Avanzados del IPN, Apartado postal 14-740, Zacatenco 07000,
México D.F, Mexico; email:jterron@cinvestav.mx
© Copyright 2013 Elsevier B.V., All rights reserved.
© MEDLINE® is the source for the MeSH terms of this document.
Go to Athens / Institution login
Click here to activate